Biocon sells 9.96% stake in contract research firm Syngene via open market

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing

Biocon
The selling price would be in the range of 560 rupees and 562.30 rupees per share, the report said
Reuters BENGALURU
2 min read Last Updated : Feb 01 2023 | 7:33 PM IST

BENGALURU (Reuters) - Indian biopharma company Biocon sold a 9.96% stake in its unit and contract research firm Syngene International through open market sale, it said in an exchange filing on Wednesday.

With the sale, the total promoter stake of Biocon in Syngene stands at 54.6%, the exchange filing showed.

Biocon did not reveal the price at which the stake was sold.

Officials at Syngene and Biocon did not immediately respond to a Reuters query seeking the reason for the stake sale and the price at which the sale was executed.

Biocon was selling the stake in Syngene to fund the acquisition of Viatris Inc's biosimilars business that it announced last year, CNBC TV-18 reported on Tuesday.

The selling price would be in the range of 560 rupees and 562.30 rupees per share, the report said.

Biocon Biologics had in February 2022 said it would buy the U.S. drug maker's biosimilars business in a deal valued at $3.34 billion.

Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing.

Biocon's shares closed up 2%, while those of Syngene added 0.74% on Wednesday.

 

(Reporting by Nallur Sethuraman in Bengaluru; Editing by Dhanya Ann Thoppil)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bioconbiocon stockStake saleSyngene International

First Published: Feb 01 2023 | 7:33 PM IST

Next Story